{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-26-002429","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.064679+00:00","generated_at":"2026-05-16T05:18:20.376528+00:00","sec_items":["2.02","8.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tonix prelim 2025: net loss $118.9M vs $130.0M; cash $207.6M funds ops into Q1 2027","bullets":["Cash & equivalents $207.6M at Dec 31, 2025; 12.79M shares outstanding as of Jan 30, 2026.","Net loss $118.9M (2025) vs $130.0M (2024); net cash used in operations $99.0M vs $60.9M.","Net product revenue $13.1M (2025) vs $10.1M (2024); Zembrace/Tosymra $11.7M vs $10.1M.","TONMYA launch Nov 17, 2025 generated $1.4M from launch to Dec 31, 2025.","Capital expenditures $3.4M in 2025 vs $0.1M in 2024; cash expected to fund ops into Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-002429","json":"https://secwatch.observer/filing/0001999371-26-002429.json","markdown":"https://secwatch.observer/filing/0001999371-26-002429.md","text":"https://secwatch.observer/filing/0001999371-26-002429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/0001999371-26-002429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/tonix-8k_020326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:18:20.376528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}